Table 2.
The prognostic value of GATA3 positivity stratified by clinico-pathological features and biological prognostic factors. Age-adjusted HRs are estimated through proportional hazard Cox models.
| Variable | Stratified Cox Regression Analysis | |
|---|---|---|
| Hazard Ratio | 95% Confidence Interval | |
| Age | ||
| <50 years | 0.92 | 0.53–1.60 |
| ≥50 years | 0.66 | 0.52–0.83 |
| Histologic Grade | ||
| 1–2 | 0.69 | 0.54–0.88 |
| 3 | 0.74 | 0.47–1.16 |
| Histologic Type | ||
| No special type | 0.71 | 0.56–0.91 |
| Lobular | 0.69 | 0.39–1.22 |
| Other | 0.35 | 0.15–0.85 |
| pT | ||
| T1 | 0.67 | 0.50–0.90 |
| T2 | 0.78 | 0.56–1.08 |
| T3 | 1.85 | 0.41–8.41 |
| pN | ||
| N0 | 0.65 | 0.48–0.87 |
| N+ | 0.76 | 0.56–1.03 |
| Stage | 0.69 | |
| I | 0.69 | 0.48–1.00 |
| II | 0.66 | 0.47–0.91 |
| III | 0.96 | 0.61–1.49 |
| ER | ||
| Negative (<1%) | 0.55 | 0.30–1.00 |
| Positive (≥1%) | 0.77 | 0.59–0.99 |
| PR | ||
| Negative (<1%) | 0.72 | 0.47–1.10 |
| Positive (≥1%) | 0.74 | 0.57–0.96 |
| Ki-67 | ||
| Negative (<20%) | 0.72 | 0.56–0.92 |
| Positive (≥20%) | 0.67 | 0.44–1.02 |
| HER2 | ||
| Negative (0–2+) | 0.64 | 0.51–0.82 |
| Positive (3+) | 1.06 | 0.66–1.71 |
| Molecular intrinsic BC subtypes | ||
| Luminal A | 0.78 | 0.54–1.14 |
| Luminal B | 0.64 | 0.42–0.98 |
| Luminal B-HER2+ | 1.17 | 0.62–2.21 |
| HER2+ | 0.66 | 0.18–2.36 |
| Triple negative | 0.69 | 0.33–1.46 |
| p53 | ||
| Wild-type pattern | 0.71 | 0.55–0.92 |
| Mutated pattern | 0.93 | 0.61–1.41 |
n, number of cases; ER, estrogen receptor; PR, progesterone receptor.